Unknown

Dataset Information

0

Effect of sacubitril/valsartan on recurrent events in the Prospective comparison of ARNI with ACEI to Determine Impact on Global Mortality and morbidity in Heart Failure trial (PARADIGM-HF).


ABSTRACT: AIMS:Recurrent hospitalizations are a major part of the disease burden in heart failure (HF), but conventional analyses consider only the first event. We compared the effect of sacubitril/valsartan vs. enalapril on recurrent events, incorporating all HF hospitalizations and cardiovascular (CV) deaths in PARADIGM-HF, using a variety of statistical approaches advocated for this type of analysis. METHODS AND RESULTS:In PARADIGM-HF, a total of 8399 patients were randomized and followed for a median of 27?months. We applied various recurrent event analyses, including a negative binomial model, the Wei, Lin and Weissfeld (WLW), and Lin, Wei, Ying and Yang (LWYY) methods, and a joint frailty model, all adjusted for treatment and region. Among a total of 3181 primary endpoint events (including 1251 CV deaths) during the trial, only 2031 (63.8%) were first events (836 CV deaths). Among a total of 1195 patients with at least one HF hospitalization, 410 (34%) had at least one further HF hospitalization. Sacubitril/valsartan compared with enalapril reduced the risk of recurrent HF hospitalization using the negative binomial model [rate ratio (RR) 0.77, 95% confidence interval (CI) 0.67-0.89], the WLW method [hazard ratio (HR) 0.79, 95% CI 0.71-0.89], the LWYY method (RR 0.78, 95% CI 0.68-0.90), and the joint frailty model (HR 0.75, 95% CI 0.66-0.86) (all P 

SUBMITTER: Mogensen UM 

PROVIDER: S-EPMC6607507 | BioStudies | 2018-01-01

SECONDARY ACCESSION(S): NCT01035255

REPOSITORIES: biostudies

Similar Datasets

2020-01-01 | S-EPMC7772612 | BioStudies
2016-01-01 | S-EPMC5076745 | BioStudies
2019-01-01 | S-EPMC6554586 | BioStudies
2020-01-01 | S-EPMC6972579 | BioStudies
2019-01-01 | S-EPMC6538576 | BioStudies
1000-01-01 | S-EPMC6251522 | BioStudies
2016-01-01 | S-EPMC5095784 | BioStudies
2017-01-01 | S-EPMC5248626 | BioStudies
2020-01-01 | S-EPMC7754944 | BioStudies
2016-01-01 | S-EPMC5253408 | BioStudies